Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Chakrabarty, Paramita ^a   Tianbai, Li ^a   Herring, Amanda ^a   Ceballos Diaz, Carolina ^a   Das, Pritam ^b   Golde, Todd E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adeno associated virus; Amyloid plaque; Amyloid precursor protein; Hippocampus; Inflammation; Interleukin 4

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 4; TAU PROTEIN;

ADENO ASSOCIATED VIRUS; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE EXACERBATION; HIPPOCAMPUS; INTERNALIZATION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; HIPPOCAMPUS; INTERLEUKIN-4; MICE; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID;

ADENO-ASSOCIATED VIRUS; MURINAE; MUS;

EID: 84864193530     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-36     Document Type: Article

References (48)

1. Inflammation, microglia, and Alzheimer's disease. Cameron B, Landreth GE, Neurobiol Dis 2010 37 503 509 10.1016/j.nbd.2009.10.006 19833208
2. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J, Nat Med 2003 9 453 457 10.1038/nm838 12612547 (Pubitemid 36460080)
3. Functions of IL-4 and control of its expression. Brown MA, Hural J, Crit Rev Immunol 1997 17 1 32 10.1615/CritRevImmunol.v17.i1.10 9034722 (Pubitemid 27068806)
4. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T, FASEB J 2010 24 3093 3102 10.1096/fj.10-155317 20371618
5. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M, Proc Natl Acad Sci U S A 2006 103 11784 11789 10.1073/pnas.0604681103 16864778 (Pubitemid 44182528)
6. Interleukin 4 induces the apoptosis of mouse microglial cells by a caspase-dependent mechanism. Soria JA, Arroyo DS, Gaviglio EA, Rodriguez-Galan MC, Wang JM, Iribarren P, Neurobiol Dis 2011 43 616 624 10.1016/j.nbd.2011.05. 010 21624466
7. Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. Nolan Y, Maher FO, Martin DS, Clarke RM, Brady MT, Bolton AE, Mills KH, Lynch MA, J Biol Chem 2005 280 9354 9362 15615726 (Pubitemid 40409629)
8. IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. Lyons A, Griffin RJ, Costelloe CE, Clarke RM, Lynch MA, J Neurochem 2007 101 771 781 10.1111/j.1471-4159.2006.04370.x 17250684 (Pubitemid 46633315)
9. Regulation of innate immune responses in the brain. Rivest S, Nat Rev Immunol 2009 9 429 439 10.1038/nri2565 19461673
10. Massive gliosis induced by interleukin-6 suppresses A{beta} deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P, FASEB J 2009 24 548 559 19825975
11. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P, J Immunol 2010 184 5333 5343 10.4049/jimmunol.0903382 20368278
12. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE, Mol Neurodegener 2011 6 16 10.1186/1750-1326-6-16 21324189
13. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD, Nat Med 2007 13 432 438 10.1038/nm1555 17351623 (Pubitemid 46559828)
14. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK, J Clin Invest 2007 117 1595 1604 10.1172/JCI31450 17549256 (Pubitemid 46871344)
15. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. Richard KL, Filali M, Prefontaine P, Rivest S, J Neurosci 2008 28 5784 5793 10.1523/JNEUROSCI.1146-08.2008 18509040
16. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA, Nat Med 2008 14 681 687 18516051 (Pubitemid 351809551)
17. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S, Brain 2009 132 1078 1092 19151372
18. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE, J Clin Invest 2006 116 193 201 16341263 (Pubitemid 43121804)
19. BRI2 (ITM2b) inhibits Abeta deposition in vivo. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, et al. J Neurosci 2008 28 6030 6036 10.1523/JNEUROSCI.0891-08.2008 18524908
20. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Mantovani A, Bonecchi R, Locati M, Nat Rev Immunol 2006 6 907 918 10.1038/nri1964 17124512 (Pubitemid 44851733)
21. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA, J Neurosci 2007 27 8309 8313 10.1523/JNEUROSCI.1781-07.2007 17670977 (Pubitemid 47219605)
22. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al. J Biol Chem 2001 276 21562 21570 10.1074/jbc.M100710200 11279122 (Pubitemid 37413154)
23. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, et al. Proc Natl Acad Sci U S A 2003 100 10966 10971 10.1073/pnas.1434398100 12939405 (Pubitemid 37140136)
24. Autophagy, amyloidogenesis and Alzheimer disease. Nixon RA, J Cell Sci 2007 120 4081 4091 10.1242/jcs.019265 18032783
25. Autophagy in the immune response to tuberculosis: clinical perspectives. Ni Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J, Clin Exp Immunol 2011 164 291 300 10.1111/j.1365-2249.2011.04381.x 21438870
26. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE, J Neurosci 2009 29 4252 4262 10.1523/JNEUROSCI.5572-08.2009 19339619
27. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Harris J, De Haro SA, Master SS, Keane J, Roberts EA, Delgado M, Deretic V, Immunity 2007 27 505 517 10.1016/j.immuni.2007.07.022 17892853 (Pubitemid 47418681)
28. p62 at the crossroads of autophagy, apoptosis, and cancer. Moscat J, Diaz-Meco MT, Cell 2009 137 1001 1004 10.1016/j.cell.2009.05.023 19524504
29. Toll-like receptor 2-independent and MyD88-dependent gene expression in the mouse brain. Naert G, Laflamme N, Rivest S, J Innate Immun 2009 1 480 493 10.1159/000225990 20375605
30. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN, J Neuroimmune Pharmacol 2007 2 222 231 10.1007/s11481-007-9069-z 18040847
31. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME, J Neurosci 2008 28 4283 4292 10.1523/JNEUROSCI.4814-07. 2008 18417708
32. The role of microglia in amyloid clearance from the AD brain. Lee CY, Landreth GE, J Neural Transm 2010 117 949 960 10.1007/s00702-010-0433-4 20552234
33. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K, Brain 2005 128 1778 1789 10.1093/brain/awh531 15857927 (Pubitemid 41373649)
34. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, et al. Nat Immunol 2010 11 155 161 10.1038/ni.1836 20037584
35. El Khoury J: Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. Hickman SE, Allison EK, J Neurosci 2008 28 8354 8360 10.1523/JNEUROSCI.0616-08.2008 18701698
36. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Majumdar A, Cruz D, Asamoah N, Buxbaum A, Sohar I, Lobel P, Maxfield FR, Mol Biol Cell 2007 18 1490 1496 10.1091/mbc.E06-10-0975 17314396 (Pubitemid 46626644)
37. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Paresce DM, Ghosh RN, Maxfield FR, Neuron 1996 17 553 565 10.1016/S0896-6273(00)80187-7 8816718 (Pubitemid 26322226)
38. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
39. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP, J Neuroinflammation 2006 3 27 10.1186/1742-2094-3-27 17005052 (Pubitemid 44575752)
40. NSAIDs and incident Alzheimer's disease. The Rotterdam Study [see comments]. Veld BA I, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH, Neurobiol Aging 1998 19 607 611 10.1016/S0197-4580(98)00096-7 10192221 (Pubitemid 29117129)
41. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ, Neurology 2010 75 1203 1210 10.1212/WNL. 0b013e3181f52db1 20811000
42. Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Golde TE, Miller VM, Alzheimers Res Ther 2009 1 5 10.1186/alzrt5 19822029
43. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Wyss-Coray T, Nat Med 2006 12 1005 1015 16960575 (Pubitemid 44353380)
44. Amor S, Puentes F, Baker D, van der Valk P, Inflammation in neurodegenerative diseases. Immunology 2010 129 154 169
45. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. Koenigsknecht-Talboo J, Landreth GE, J Neurosci 2005 25 8240 8249 10.1523/JNEUROSCI.1808-05.2005 16148231 (Pubitemid 41292118)
46. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H, J Immunol 2008 181 6503 6513 18941241
47. Notch and presenilin regulate cellular expansion and cytokine secretion but cannot instruct Th1/Th2 fate acquisition. Ong CT, Sedy JR, Murphy KM, Kopan R, PLoS One 2008 3 2823 10.1371/journal.pone.0002823 18665263
48. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Lee J, Chan SL, Mattson MP, Neuromolecular Med 2002 2 29 45 10.1385/NMM:2:1:29 12230303 (Pubitemid 37012508)